TrialActa dermato-venereologica2021

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.

Mette Deleuran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.